中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

43 records (took 0.024 seconds)

    Indol-3-YL-2-oxoacetamide compounds and methods of use thereof
    11.
    发明授权
    Indol-3-YL-2-oxoacetamide compounds and methods of use thereof 有权

    公开(公告)号：US06903104B2

    公开(公告)日：2005-06-07

    申请号：US10310711

    申请日：2002-12-05

    Applicant: Chiung-Tong Chen ,  Shu-Jen Chen ,  Ming-Chu Hsu ,  Der-Ren Hwang ,  Wen-Tai Li ,  Chu-Chung Lin

    Inventor： Chiung-Tong Chen ,  Shu-Jen Chen ,  Ming-Chu Hsu ,  Der-Ren Hwang ,  Wen-Tai Li ,  Chu-Chung Lin

    IPC: C07D401/12 ,  C07D403/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  A61K31/405 ,  C07D407/12 ,  C07D413/12

    CPC classification number: C07D401/12 ,  C07D403/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14

    Abstract: The invention is based on the discovery that certain 3-oxoacetamideindolyl compounds have potent anticancer and anti-angiogenic activity. The 3-oxoacetamideindolyl compounds are of the following formula. In this formula, each R1 is independently isoxazolyl, thiazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,3-benzothiazolyl, quinolyl, isoquinolyl, thionaphthenyl, or benzofuranyl, each being optionally substituted with 1-6 independent R5; or when taken together with R2 and the nitrogen atom to which they are attached form a 5-8 membered ring comprising C, N, S, or O atoms wherein any atom is optionally substituted with an independent R5. Each R2 is independently H, C1-C10 alkyl, or aryl, each being optionally substituted with 1-4 independent R5; or when taken together with R1 and the nitrogen atom to which they are attached form a 5-8 membered ring comprising C, N, S, or O atoms wherein any atom is optionally substituted with an independent R5. Each R3 is independently C3-C10 cycloalkyl, C4-C10 cycloalkenyl, isoxazolyl, furanyl, thiophenyl, thiazolyl, imidazolyl, pyridyl, or heterocyclyl, each being optionally substituted with 1-4 independent R5. Each R4 is independently H, NO2, halo, CN, R7, OR7, CO2R7, SR7, NR7R7, C(O)R7, C(O)NR7R7, OC(O)R7, S(O)2R7, S(O)2NR7R7, NR7C(O)NR7R7, NR7C(O)R7, NR7(COOR7), NR7S(O)2NR7R7, NR7S(O)2R7, or S(O)2OR7.

    Method for simultaneously fabricating salicide and self-aligned barrier
    14.
    发明授权
    Method for simultaneously fabricating salicide and self-aligned barrier 失效
    同时制造自对准和自对准屏障的方法

    公开(公告)号：US5924010A

    公开(公告)日：1999-07-13

    申请号：US740512

    申请日：1996-10-30

    Applicant: Shu-Jen Chen ,  Jiunn-Hsien Lin ,  Chih-Ching Hsu

    Inventor： Shu-Jen Chen ,  Jiunn-Hsien Lin ,  Chih-Ching Hsu

    IPC: H01L21/28 ,  H01L21/336

    CPC classification number: H01L29/665 ,  H01L21/28052

    Abstract: A method of fabricating salicide and self-aligned barrier simultaneously is disclosed. The initial steps include sputtering a metal stack (Ti--TiN--Ti) and forming a salicide layer by thermally reacting the metal stack and the wafer followed by a chemical etching which removes the unreacted portions of the metal stack. The portions of the metal stack on Si can react with Si to form a TiSi.sub.2 layer, thus forming TiSi.sub.2 --TiN--TiSi.sub.2. The TiSi.sub.2 layer over the TiN layer acts as a mask in the chemical etching and protects the TiN layer from been etched. The diffusion barrier layer is thus formed simultaneously within the fabricating of salicide.

    Abstract translation: 公开了一种同时制造自对准屏障的方法。 初始步骤包括溅射金属叠层（Ti-TiN-Ti）并通过使金属叠层和晶片热反应，然后通过化学蚀刻形成硅化物层，从而除去金属堆叠体的未反应部分。 Si上的金属堆叠部分可与Si反应形成TiSi2层，从而形成TiSi2-TiN-TiSi2。 TiN层上的TiSi2层用作化学蚀刻中的掩模，并保护TiN层免受蚀刻。 因此，在制造硅化物的同时形成扩散阻挡层。

    PHARMACOLOGICALLY INDUCED TRANSGENE ABLATION SYSTEM
    16.
    发明申请
    PHARMACOLOGICALLY INDUCED TRANSGENE ABLATION SYSTEM 审中-公开
    药理学诱导转基因系统

    公开(公告)号：US20130023033A1

    公开(公告)日：2013-01-24

    申请号：US13638015

    申请日：2011-03-28

    Applicant: James M. Wilson ,  Shu-Jen Chen ,  Anna P. Tretiakova

    Inventor： James M. Wilson ,  Shu-Jen Chen ,  Anna P. Tretiakova

    IPC: C12N7/01 ,  C12N5/10 ,  C12N1/21 ,  C12N15/63

    CPC classification number: C12N15/86 ,  A61K48/0066 ,  C07K2319/715 ,  C07K2319/80 ,  C12N9/22 ,  C12N2750/14143 ,  C12N2800/30 ,  C12N2800/80 ,  C12N2830/002 ,  C12N2830/003 ,  C12N2830/005 ,  C12N2830/006 ,  C12N2830/20 ,  C12N2840/203

    Abstract: The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as “PITA” (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript.

    Abstract translation: 本发明涉及基因治疗系统，其被设计用于使用使用内置安全机制工程改造的复制缺陷病毒组合物将治疗产品递送给受试者，所述安全机制永久地或临时地用于消融治疗性基因产物 药物剂 - 优选口服制剂，例如丸剂。 本发明部分地基于申请人开发综合方法，本文称为PITA（药理学诱导的转基因消融），用于消融转基因或负调节转基因表达。 在这种方法中，使用复制缺陷病毒递送编码治疗产物（RNA或蛋白质）的转基因，使其在受试者中表达，但是可以通过施用药理学试剂来逆转或不可逆地关闭; 例如通过施用诱导特异于转基因或其RNA转录物的消融体表达的小分子。

Patent Agency Ranking